动物造模,乙型病毒性肝炎 z-bio 2022-01-07 793

　　There are approximately 240 million chronic hepatitis B patients in the world, of which 15% to 40% will develop serious liver diseases, such as liver cirrhosis and hepatocellular carcinoma. As a result, more than 780,000 people die every year. Despite the manufacture of HBV vaccines and antiviral drugs, hepatitis B is still an infectious disease that seriously threatens human health. HBV infection and replication cannot directly damage liver cells. The clinical symptoms are caused by the complex interaction between the host's immune response and the virus, which leads to the development of liver cirrhosis and liver cancer. Due to the limitations of the HBV host, there is still no ideal HBV animal model to study how HBV interacts with the host to cause chronic infection. At the same time, the mechanism by which chronic infection leads to liver cirrhosis, cirrhosis and hepatocellular carcinoma is still unclear. This review introduces the existing HBV animal models and various models that can be used by researchers in future HBV research based on the types of infectious pathogens, pathophysiological changes and the development of liver cancer, as well as their applications and comparisons. Introduction.